As a platform company developing drugs against a newly identified class of enzymes, we will have found and characterized this class of enzymes and will have paved a novel inroad into the proprietary development of disease-modifying therapies
We are initially targeting Parkinson’s disease and developing cures for multiple aging-dependent diseases, including other neurodegenerative diseases, Type II diabetes, heart disease and cancer.
We innovate to improve lives and we’ve received an impressive collection of awards and recognitions. Here are a few of our latest distinctions.
